Oramed Pharmaceuticals Inc.
ORMP
$4.48
$0.102.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 104.01% | 282.76% | -79.32% | 264.20% | 273.88% |
| Total Depreciation and Amortization | 3.33% | 0.00% | -3.23% | 3.33% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -43.29% | -340.40% | 81.31% | -319.51% | -350.82% |
| Change in Net Operating Assets | -203.04% | 1,124.26% | -93.33% | 462.94% | -67.66% |
| Cash from Operations | 93.14% | -525.54% | 71.32% | 54.03% | -0.45% |
| Capital Expenditure | 60.00% | -150.00% | -- | 100.00% | -33.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 122.13% | -1,058.32% | -104.38% | 169.94% | -332.22% |
| Cash from Investing | 122.12% | -1,057.24% | -104.39% | 169.94% | -332.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -1,010.53% | 2.70% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 99.25% | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 81.19% | -158.52% | -1,010.53% | 2.70% | -- |
| Foreign Exchange rate Adjustments | -636.36% | 130.14% | -1,925.00% | -90.00% | 4,100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 106.24% | -425.43% | -117.13% | 161.96% | -392.19% |